Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma
Increasing evidences demonstrate that CD227 plays a crucial role in the development and progression of breast cancer. However, the function of CD227 in breast carcinoma was still controversial and the investigation on CD227 in Asian race was scarce.
To investigate the relationship between CD227 and tumor characteristics of breast carcinoma, CD227, estrogen receptor (ER), progesterone receptor (PR), Her2⁄neu and Ki-67 were detected by immunohistochemistry in a series of 227 patients. The Kaplan–Meier method and log-rank tests were used to estimate the correlation between CD227 expression and patients’ prognosis. Furthermore, in vitro invasion assay was performed to examine the effect of CD227 on the invasiveness of breast carcinoma cells after transfection with CD227 cDNA or antisense phosphorothioate oligodeoxynucleotides (ASODN) against CD227 mRNA.
Our data demonstrate that the cytoplasm staining and high expression of CD227 were positively related to the aggressiveness of breast cancer. Both circumferential membrane staining and cytoplasm staining were associated with lymph node metastasis. Moreover, the cytoplasm staining and overexpression of CD227 were found to be related to Her-2/neu positivity, higher Ki-67 positivity and poorer survival of patients. We further demonstrated that the invasion ability of breast carcinoma cells could be enhanced or inhibited by CD227 cDNA or ASODN, respectively.
We conclude that the aberrant expression of CD227, especially cytoplasm staining could be predictive for tumor aggressiveness, lymph node metastasis, poorer outcome of patients with breast cancers. And CD227 could promote the invasion ability of breast cancer cells, suggesting a potential role of CD227 as an oncogene in breast carcinoma.
KeywordsBreast carcinoma CD227 Tumor characteristics Invasiveness Antisense phosphorothioate oligodeoxynucleotides Prognosis
- Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ (2010) Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 34(11):1637–1646. doi:10.1097/PAS.0b013e3181f5539c PubMedGoogle Scholar
- Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian B, Colorectal Cancer Study G (2001) Evaluation of the United States Food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7(6):1669–1675PubMedGoogle Scholar
- Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L (1999) Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 17(5):1535–1544PubMedGoogle Scholar
- de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast. Histopathology 51(2):227–238. doi:10.1111/j.1365-2559.2007.02754.x PubMedCrossRefGoogle Scholar
- Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076–1087PubMedGoogle Scholar
- Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB et al (1991) Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 9(7):1113–1123PubMedGoogle Scholar
- McGuckin MA (2001) CD227 (MUC1)—summary and workshop report. In: Mason D (ed) Leucocyte typing VII. Oxford University, Oxford, pp 54–56Google Scholar
- Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295–1304. doi:10.1038/modpathol.3800445 PubMedCrossRefGoogle Scholar
- Smith NL, Catrou PG, Payne G, Kellogg AE (2004) Patterns of expression of the DS6-glycoform of MUC1 correlates with known prognostic indicators in breast cancer. In: AACR Meeting Abstracts, 2004. p 239Google Scholar
- van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 51(3):322–335. doi:10.1111/j.1365-2559.2007.02757.x PubMedCrossRefGoogle Scholar
- Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64(11):3780–3789. doi:10.1158/0008-5472.CAN-03-1460 PubMedCrossRefGoogle Scholar